- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02178436
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
November 5, 2023 updated by: Mohammed Najeeb Al Hallak
Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic).
Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Overview
Status
Completed
Conditions
Detailed Description
Primary Objectives:
- Phase I: To determine the recommended phase 2 dose (RP2D) of gemcitabine, nabpaclitaxel and selinexor for untreated metastatic pancreatic cancer [COMPLETED]
- Phase I: To determine the safety profile of gemcitabine, nab-paclitaxel and selinexor [COMPLETED]
- Phase II: To test whether the combination of gemcitabine and selinexor improves the median overall survival of patients with metastatic pancreatic cancer who have failed frontline non-gemcitabine containing regimens beyond 5.6 months (median overall survival of patient receiving gemcitabine only based on historical data.
Secondary Objectives:
- To determine objective response rate to the combination of gemcitabine and selinexor using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- To assess safety of selinexor in combination with gemcitabine in phase II portion of the study
- To determine progression free survival (PFS) in patients treated with gemcitabine and selinexor
- To determine the influence of selinexor and gemcitabine on the nuclear expression and localization of tumor suppressor gene proteins.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Written informed consent in accordance with federal, local, and institutional guidelines
- Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Platelet count >= 100,000/mm^3
- Bilirubin < 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 times ULN)
- Alanine aminotransferase (ALT) < 2.5 times ULN
- Serum creatinine =< 1.5 mg/dL
- Serum albumin >= 3.0 g/dL
- Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
- Patients with history of previously treated malignancies who have no evidence of disease for last five years are allowed to participate
Exclusion Criteria:
- Patients who are pregnant or lactating
- Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 3 weeks prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1 day 1
- Major surgery within four weeks before cycle 1 day 1
Unstable cardiovascular function:
- Symptomatic ischemia, or
- Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular [AV] block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB] will not be excluded), or
- Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3, or
- Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose
- Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
- Known to be HIV seropositive who are on anti-HIV drugs because of the unknown interactions between these drugs and the study agents
- Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen)
- Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months
- Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
- Grade >= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1
- History of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1
- Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity based on physician's assessment
- Serious psychiatric or medical conditions that could interfere with treatment
- Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1
- Concurrent therapy with approved or investigational anticancer therapeutic
- Presence of clinically significant ascites
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)
Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15.
Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
|
Experimental: Group II: Phase II Group I (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15.
Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles.
Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
|
Correlative studies
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
|
Experimental: GroupIII: Phase II Group II (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15.
Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-stabilized Nanoparticle Formulation Combination (Phase Ib)
Time Frame: 28 days
|
MTD is defined as the lowest dose for which less than a third of patients experience a dose limiting toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
|
28 days
|
Proportion of Patients With a Toxic Event, Graded According to NCI CTCAE Version 4.03
Time Frame: Up to 2 years
|
The reported output is the proportion of patients that had a toxic event along with the associated 90% Wilson's confidence interval.
|
Up to 2 years
|
Overall Survival (Phase II)
Time Frame: Up to 7 months post treatment initiation
|
Estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed at least one 4-week treatment cycle) using the Kaplan-Meier method.
|
Up to 7 months post treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects the Study Drug Combination Has on Participants
Time Frame: Day 1 of course 1 (before selinexor administration, 1, 2, 4 and 8 hours after selinexor administration) and days 2, 3 and 8
|
Pharmacodynamics of selinexor in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation
|
Day 1 of course 1 (before selinexor administration, 1, 2, 4 and 8 hours after selinexor administration) and days 2, 3 and 8
|
Proportion of Patients With a Response
Time Frame: Up to 2 years
|
Point and 90% Wilson's confidence intervals will be estimated to describe response rate.
If the best observed clinical response was complete response or partial response, we consider that the patient responded.
|
Up to 2 years
|
Progression Free Survival (Phase II)
Time Frame: Up to 2 years
|
Estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed at least one 4-week treatment cycle) using the Kaplan-Meier method.
Both progression and death are considered events for this analysis.
|
Up to 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Gene Expression (Including Forkhead Box Protein O, I-kappaB, Cyclin-dependent Kinase Inhibitor 1B, Par4 and Phosphorylated Signal Transducer and Activator of Transcription 3) (Phase II)
Time Frame: Baseline to up to 2 years
|
Seven patients in each group will yield a two-sided 90% confidence interval with a distance from the mean change to the limits of 0.75 standard deviation units.
A two-sided p-value of 0.10 will be used for all analyses.
|
Baseline to up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mohammed N Al Hallak, M.D., Barbara Ann Karmanos Cancer Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2014
Primary Completion (Actual)
November 27, 2021
Study Completion (Actual)
April 5, 2023
Study Registration Dates
First Submitted
June 23, 2014
First Submitted That Met QC Criteria
June 26, 2014
First Posted (Estimated)
June 30, 2014
Study Record Updates
Last Update Posted (Actual)
November 7, 2023
Last Update Submitted That Met QC Criteria
November 5, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Adenocarcinoma
- Pancreatic Neoplasms
- Carcinoma, Acinar Cell
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
- Gemcitabine
Other Study ID Numbers
- 2013-133
- NCI-2014-01249 (Other Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acinar Cell Adenocarcinoma of the Pancreas
-
National Cancer Institute (NCI)TerminatedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IV Pancreatic CancerUnited States
-
John DeWittAmerican Society for Gastrointestinal Endoscopy; Pinnacle Biologics Inc.CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic CancerUnited States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)TerminatedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IIB Pancreatic CancerUnited States
-
National Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterCompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage I-III Pancreatic CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
Yale UniversityNational Cancer Institute (NCI)Active, not recruitingAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage I Pancreatic CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Mayo ClinicCompletedUnspecified Adult Solid Tumor, Protocol Specific | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States